传统医学的缓解性结肠炎的机制:调节肠道屏障功能
Qiuyun Xu1, Yuan Yao1, Yongchao Liu1
1Department of Immunology, School of Medicine, Nantong University, Nantong, Jiangsu, China.
Frontiers in pharmacology
|October 25, 2023
概括
传统草药通过恢复肠道屏障功能来治疗性结肠炎 (UC) 是有前途的. 本综述探讨了调节肠道微生物群和炎症等机制,为UC提供了新的治疗途径.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,发病率不断增加,有效治疗方法有限.
- 肠道屏障功能障碍,受遗传学,免疫力,微生物群和环境的影响,是UC病变的一个关键因素.
- 传统草药为UC提供了潜在的治疗策略,需要对其机制进行调查.
研究的目的:
- 审查草药和天然化合物对UC模型中的结肠炎症的影响.
- 阐明这些传统药物调节肠道屏障功能的机制.
- 讨论涉及的信号通路,并提供未来的研究方向.
主要方法:
- 对大肠炎动物模型中草药效应研究的文献综述.
- 分析机制,包括紧密结合蛋白,粘膜,肠道微生物群和炎症媒介.
- 检查信号通路,例如NF-κB/MAPK,PI3K和HIF-1α.
主要成果:
- 草药可以缓解结肠炎症和结肠炎症模型中的症状.
- 关键机制包括调节肠道屏障完整性,肠道微生物群和氧化应激.
- 传统疗法调节炎症通路,这对肠道平衡至关重要.
结论:
- 草药和化合物通过恢复肠道屏障功能,显示出UC治疗的显著潜力.
- 了解这些机制为开发针对UC的新有效疗法提供了基础.
- 需要进一步的研究来将这些发现转化为性结肠炎患者的临床应用.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
149
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
149
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
438
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
438
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
517
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
517
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
461
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
461
Inflammatory Bowel Disease IV: Pharmacological Management
134
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
134
Inflammatory Bowel Disease V: Surgical Management
149
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
149


